NERA Insights Webinar | Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity

17 November 2020
Hosted By: NERA Economic Consulting

Mistakes in obtaining proper patent coverage could cost a pharmaceutical company valuable property rights. Securing and then listing patents in the FDA’s Orange Book provides companies the ability to protect the substantial investment made during drug development, which is important as companies commonly face competition at all stages of drug development and commercialization from competing drug developers and generics.

In this free, one-hour webinar, held on 17 November at 12:00–1:00 pm EST, Former Senior Consultant Dr. Omar Robles and Finnegan Attorneys Dr. Ryan O’Quinn and Amy Fulton will:

  • Provide an overview of the FDA Orange Book, including what to list (and what not to list);
  • Review recent congressional activity in pharmaceutical patents, focusing on new federal and state legislation;
  • Highlight the FDA’s recent policy changes; and
  • Discuss trends in patent issuance and patent exclusivity from 2011 to 2018.
View Recording


NERA Economic Consulting is accredited by the State Bar of California (#19366) as a provider of continuing legal education. The program is being held with the intention that its attendees qualify for 1.0 CLE credit hour in areas of professional practice. The program is appropriate for experienced attorneys only.


Dr. Omar Robles
Former Senior Consultant, NERA Economic Consulting

Amy Fulton
Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Dr. Ryan O'Quinn
Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Dr. Omar Robles is a former Senior Consultant in NERA’s Intellectual Property and Antitrust and Competition Practices. He has worked on numerous cases in the life sciences industry, including cases pertaining to dietary supplements, pharmaceutical products, and medical devices. Dr. Robles actively consults on commercial success, harm resulting from patent infringement (damages, reasonable royalty and lost profits, and irreparable harm), the relevant antitrust market, and harm resulting from reverse payment settlements. His engagements have included products approved in the US, Canada, and Latin America. Dr. Robles is a Lecturer at the University of California’s School of Public Health where he teaches a course on regulatory science and drug development. Dr. Robles holds a PhD and MA in economics from Harvard University, and an MBA from DePaul University. 

Amy Fulton’s practice focuses on patent litigation in federal court and before the US International Trade Commission (ITC). Ms. Fulton’s experience includes all aspects of pre-trial preparation, including responding to discovery requests, drafting legal briefs, and assisting with deposition preparation. She also has significant experience managing the electronic review of documents for complex litigation matters, overseeing production of documents, and drafting privilege logs. Ms. Fulton received her JD from Suffolk University Law School.

Dr. Ryan O’Quinn focuses his practice on US district court litigation, appeals, and contested proceedings at the US Patent and Trademark Office (USPTO). Dr. O’Quinn maintains an active patent prosecution and client counseling practice, including portfolio management, preparation of opinions, and delivery of strategic guidance to clients of all sizes across various industries. His practice covers a range of technologies, including pharmaceuticals, biotechnology, immunotherapy, medical devices, computer software, business methods, vending technologies, and mechanical systems. Prior to joining Finnegan, Dr. O’Quinn conducted doctoral and undergraduate research in cellular and molecular biology and biomedical engineering. He is an Adjunct Professor at George Washington University Law School in the Scholarly Writing Program, where he teaches and supervises student members of the Federal Circuit Bar Journal.

Web Form

To contact us about this event, please click here.